Rhabdomyolysis in a patient treated with colchicine and atorvastatin

Annals of Pharmacotherapy

Volumn 40, Issue 7-8, 2006, Pages 1466-1469

  Tufan, Abdurrahman ^a   Dede, Didem Sener ^a   Cavus, Safak ^a   Altintas, Neriman Defne ^a   Iskit, Alper Bektas ^a   Topeli, Arzu ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Atorvastatin; Colchicine; P glycoprotein; Rhabdomyolysis

Indexed keywords

ATORVASTATIN; COLCHICINE; CREATINE; CREATINE KINASE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; AMYLOIDOSIS; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG SAFETY; DRUG UPTAKE; DYSPNEA; FATIGUE; GAIT DISORDER; HOSPITAL INFECTION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MENTAL DISEASE; MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; NEPHROTIC SYNDROME; OLIGURIA; PATIENT MONITORING; PNEUMONIA; PRIORITY JOURNAL; RHABDOMYOLYSIS;

ADULT; ANTICHOLESTEREMIC AGENTS; COLCHICINE; CREATINE KINASE; DRUG INTERACTIONS; HEPTANOIC ACIDS; HUMANS; MALE; P-GLYCOPROTEIN; PYRROLES; RHABDOMYOLYSIS;

EID: 33747008937     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H064     Document Type: Article

References (18)

1. Waters DD. Safety of high-dose atorvastatin therapy. Am J Cardiol 2005;96:69F-75F.
2. Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 2004;147:956-65.
3. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141-60.
4. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-70.
5. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998;28:48-59.
6. Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003;55:53-81.
7. Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001;18:800-6.
8. Bogman K, Peyer AK, Torok M, Kusters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001;132:1183-92.
9. Hsu WC, Chen WH, Chang MT, Chiu HC. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatiri. Clin Neuropharmacol 2002;25:266-8.
10. Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004;30:799-802.
11. Alayli G, Cengiz K, Cantürk F, Durmus D, Akyol Y, Menekse EB. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother 2005;39:1358-61. Epub 24 May 2005. DOI 10.1345/aph.1E593
12. Atasoyu EM, Evrenkaya TR, Solmazgul E. Possible colchicine rhabdomyolysis in a fluvastatin-treated patient (letter). Ann Pharmacother 2005;39:1368-9. Epub 14 Jun 2005. DOI 10.1345/aph1E653
13. Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004;24:1784-92.
14. Tsai J, Chern TL, Hu SC, Lee CH, Wang RB, Deng JF. The clinical implication of theophylline intoxication in the emergency department. Hum Exp Toxicol 1994;13:651-7.
15. Kruhoffer PK, Moelby L, Andersen PI. Rhabdomyolysis and acute theophylline overdose. Nephrol Dial Transplant 1992;7:883-4.
16. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
17. Garberoglio C, Dudas M, Casper ES, Bertino J, Cordon-Cardo C. Expression of P-glycoprotein in normal muscle cells and myogenic tumors. Arch Pathol Lab Med 1992;116:1055-61.
18. Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005;156:319-29.